WEST PHARMACEUTICAL SERVICES INC — Form 8-K
Filed October 26, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
West Pharmaceutical Services Inc. executed a new $950M credit agreement on October 26, 2026, replacing its prior 2019 facility. The facility consists of a $200M Term A Loan (due 2031) and revolving commitments (Revolver A and B) due 2031, with multiple lenders led by Bank of America. Interest margins range 1.0%–1.75% depending on leverage; commitment fees 0.125%–0.225%. No material changes from prior facility structure; standard refinancing with normal covenants and terms.
Why this rating
Routine refinancing of existing credit facility. $950M is ~6% of $15.7B market cap; maturity extension ordinary; no new facilities, no debt reduction. Standard administrative event.
See more from October 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.